학술논문
Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings
Document Type
Original Paper
Author
Martin-Quesada, Ana Isabel; Llabres-Valentí, Elisenda; Montesdeoca-Godoy, Cristina María; Martín-Abreu, Carla; Alemán-Sánchez, Cristina; Rodríguez-Pérez, Natalia; Herrero-Márquez, Alicia; Cruz-Jurado, Josefina; Hernández-Sosa, María; Marrero-García, Melody; DelPino-Hernández, Cristina Victoria; Hernández-Sarmiento, Samuel José; Rodríguez-Capote, Alejandra; Pérez-Méndez, Lina; Núñez-Hernández, Isaac
Source
Clinical and Translational Oncology. :1-5
Subject
Language
English
ISSN
1699-3055
Abstract
Purpose: Tri-weekly carboplatin is an established neoadjuvant treatment for triple-negative breast cancer, enhancing pathological complete response (pCR) and overall survival. This study explores if weekly carboplatin provides lower toxicity and comparable pCR rates.Methods/patients: A retrospective multicenter study (January 2021 to March 2023) compares outcomes of weekly and tri-weekly carboplatin.Results: Among 104 participants, 60% received weekly and 40% tri-weekly treatments. Weekly administration had fewer discontinuations (56.5 vs. 70.7%, p = 0.154). Both schedules exhibited similar overall toxicity (p = 0.087), with slightly higher grade 3–4 toxicity in the tri-weekly group (56.1 vs. 48.4%, p = 0.126). Hematological toxicity was comparable, but the weekly group experienced more diarrhea (p = 0.432) and asthenia (p = 0.012). Weekly treatment correlated with more frequent breast-conserving surgeries (p = 0.004). pCR rates were 50% with weekly and 61% with tri-weekly regimens (p = 0.186).Conclusions: Weekly carboplatin exhibited comparable toxicity, a trend toward fewer interruptions, and similar pCR rates. Prospective studies are essential for validating these findings.